| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2009 , Vol 51 , Num 2
FORMULATION AND EVALUATION OF COENCAPSULATED RIFAMPICIN AND ISONIAZID LIPOSOMES USING DIFFERENT LIPIDS
Acharya and B.M. Reddy College of Pharmacy, Bangalore, Karnataka State, India
Viewed :
18069
-
Downloaded :
7918
An attempt has been made to design suitable co encapsulated liposomal drug delivery system for rifampicin and isoniazid and for the evaluation of these systems in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized for size distribution analysis, drug entrapment, drug release profiles and vesicular stability carried out. In vivo drug kinetics and histopathology study were carried out on normal healthy albino rats. For co encapsulated liposome of rifampicin and isoniazid various pharmacokinetic parameters were determined. Coencpsulated liposomal formulations elevated plasma elimination half life and decreased elimination rate constants for rifampicin and isoniazid, in vivo studies suggested that co encapsulation retard the release of drug from circulation compared to free drug due to slow drug release into systemic circulation. A three fold increase in the area under plasma rifampicin and isoniazid concentration-time curve for encapsulated drug. This formulation also reduces the accumulation of drug in the liver kidney and lungs. It is evident from this study that liposomes could be promising delivery systems for rifampicin and isoniazid with prolonged drug release profiles and reasonably good stability characteristics.
Keywords :
LIPOSOME, RIFAMPICIN, ISONIAZID, TUBERCULOSIS